ArticleJACC. Advances2026
Machine Learning of Echocardiographic Left Ventricular Myocardial Radiomics for Identification of Transthyretin Amyloid Cardiomyopathy.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is an important cause of heart failure (HF) with increased left ventricular (LV) wall thickness that can be challenging to distinguish from other LV hypertrophic processes. Echocardiographic myocardial radiomic texture analysis may identify imperceptible amyloid-induced structural changes.
objectivesThe study aims to develop and validate an echocardiography-based machine learning model using myocardial radiomics to identify ATTR-CM.
methodsIn this retrospective and prospective multicenter study, 854 echocardiographic scans were analyzed. Conventional and novel radiomic features were extracted from parasternal short-axis views at basal, mid, and apical LV levels, with incorporated age and sex from echocardiogram metadata. A machine learning pipeline was developed using a balanced training set (150 ATTR-CM, 150 nonamyloid HF). Performance was evaluated on an independent internal validation set (50 ATTR-CM, 399 nonamyloid HF) and an external validation set (10 ATTR-CM, 10 immunoglobulin light-chain-amyloid, 10 hypertrophic cardiomyopathy, 75 nonamyloid HF).
resultsIn internal validation, the model achieved 86% sensitivity (95% CI: 73.8%-93%), 92% specificity (95% CI: 88.9%-94.3%), 57.3% positive predictive value (95% CI: 46.1%-67.9%), 98.1% negative predictive value (NPV) (95% CI: 96.2%-99.1%), and receiver operating characteristic-area under the curve 0.938 (95% CI: 0.891-0.985). Performance was consistent in the external validation (100% sensitivity, 78.9% specificity, 33.3% positive predictive value, 100% NPV, and receiver operating characteristic-area under the curve of 0.917). The model correctly classified 77.3% of nonamyloid HF, 70% of AL-amyloid cases, and 100% of hypertrophic cardiomyopathy cases as non-ATTR in subgroup analysis.
conclusionsWe developed an echocardiographic radiomics-based tool to identify ATTR-CM with excellent discrimination and very high NPV in a cohort that approximates clinical experience. These preliminary findings require validation in larger, more diverse cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.